B+
Bull case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
PRTA
ProthenaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 cash and restricted cash was $289.1 million, and the partnered pipeline offers contingent clinical milestones and royalties. A favorable PRX019 decision could bring a $55 million milestone.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29.
What can break
Clinical failure, delay, or a decision not to advance partner-controlled programs could eliminate anticipated milestones. [#SEC-8K-2026-08-06]
Momentum
56
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $13.00 · Bear $4.50Analysis 2026-10-22; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $19.60
Why
Momentum56 · Δ7d -24.5
Value41 · Δ7d -0.1
Sentiment55 · Δ7d -25.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29.
- • Sentiment remains the lead driver in the composite, 7D delta -25.5.
Contradictions & invalidation
- • Clinical failure, delay, or a decision not to advance partner-controlled programs could eliminate anticipated milestones. [#SEC-8K-2026-08-06]
- • Q2 net cash used in operating and investing activities was $25.7 million; the pace of future spending and year-end cash guidance require monitoring. [#SEC-8K-2026-08-06]
- • The principal trials are partner-controlled, major Phase 3 completions are not expected until 2029, and research collaborations have uncertain timing and economics.
Catalyst clock
2026-10-29
Bristol Myers Squibb decision on PRX019
Lead driver: Sentiment · See AI snapshot
Momentum
56
8% active weight
Current posture
7d trendFlat
Δ7d
-24.5
Δ21d
+7.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
55
45% active weight
Current posture
7d trendSoftening
Δ7d
-25.5
Δ21d
-43.4
Why this grade
Composite grade D. Momentum 56.3 / Value 40.6 / Sentiment 55.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$452.28M
Beta
-0.11
Shares Out
51.34M
P/E (TTM) · Derived
-1.9
P/S (TTM)
41.56
P/FCF (TTM) · Derived
-7.52
Rev YoY
-77.1%
EPS YoY
-84.7%
Gross Margin
+93.2%
Op Margin
-109.8%
Net Debt
-$299.16M
Current Ratio
25.05
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data